Market research
326030.KO SK Biopharmaceuticals Co., Ltd
KO KRW Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7T
- P/E ratio
- Not available
- Analyst target
- 130333.336
- Dividend yield
- Not available
- Beta
- 0.74
Profile
Company facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KR7326030004
- Market cap
- 7T
- P/E ratio
- Not available
- Analyst target
- 130333.336
- Dividend yield
- Not available
- Beta
- 0.74
About
About SK Biopharmaceuticals Co., Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 326030.KO discussion.
5 years, 5 months ago
SK Biopharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 6.2% below its 200 day moving average.
From a valuation standpoint, the stock is 3234.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 285.7.
Based on the above factors, SK Biopharmaceuticals Co., Ltd gets an overall score of 0/5.